Defending Tomorrow – Today

Elusys Therapeutics is a subsidiary of NightHawk Biosciences, an ecosystem of companies dedicated to developing and deploying novel biodefense solutions to enable fast, effective, and durable treatment and protection against infectious agents. The NightHawk ecosystem is designed to accelerate biodefense innovation and support the delivery of our anthrax antitoxin ANTHIM® (obiltoxaximab) to strategic government partners.
ANTHIM® (obiltoxaximab)

Anthrax is a disease caused by Bacillus anthracis and is regarded as a top (“Category A”) biological warfare and bioterrorism threat. Obiltoxaximab is a monoclonal anthrax antitoxin licensed as ANTHIM® in the United States and Canada and as NYXTHRACIS® in the United Kingdom and the European Union.

ANTHIM® has been delivered to the US Strategic National Stockpile as the result of a successful multi-year partnership with the US government. Elusys was also contracted as of 2022 to deliver ANTHIM to the Public Health Agency of Canada.

Click below to learn more regarding anthrax and our products.